US2016039877A1PendingUtilityA1
Compositions and methods of using islet neogenesis peptides and analogs thereof
Assignee: SHENZHEN HIGHTIDE BIOPHARMACEUTICAL LTDPriority: Mar 15, 2013Filed: Mar 15, 2013Published: Feb 11, 2016
Est. expiryMar 15, 2033(~6.6 yrs left)· nominal 20-yr term from priority
A61P 5/48A61P 3/08A61P 3/10A61P 29/00A61P 25/00A61P 1/16A61K 38/00C07K 14/4738C07K 7/08C07K 14/4733C07K 7/02C07K 14/475C07K 14/4705
60
PatentIndex Score
0
Cited by
0
References
0
Claims
Abstract
The invention provides peptides and analogs of INGAP and HIP peptides. The peptides and analogs can be used in methods for treating various diseases and conditions. Such diseases and conditions can include impaired pancreatic function, treating a metabolic disease, for example, diabetes, both type 1 and type 2 diabetes, islets induction, expansion and proliferation for transplantation, promoting neuroprotection or nerve regeneration, promoting liver regeneration or inhibiting inflammation.
Claims
exact text as granted — not AI-modified1 . A peptide or analog thereof comprising a sequence selected from the group consisting of:
IGLHDPSHGTLPAGS;
(SEQ ID NO: 7)
and
IGLHDPSHGTLPAG.
(SEQ ID NO: 73)
2 . The peptide or analog of claim 1 , wherein the peptide or analog comprises a peptide or analog selected from:
IGLHDPSHGTLPAGS;
(SEQ ID NO: 7)
IGLHDPSHGTLPAG;
(SEQ ID NO: 73)
IGLHDPSHGTLPAGSK;
(SEQ ID NO: 9)
IGLHDPSHGTLP(Aib)GS;
(SEQ ID NO: 10)
IGLHDPSHGTLP(N-methyl-L-Ala)GS;
(SEQ ID NO: 11)
Ac-IGLHDPSHGTLPAGS;
(SEQ ID NO: 12)
(D-Ile)GLHDPSHGTLPAGS;
(SEQ ID NO: 13)
(L-NorVal)GLHDPSHGTLPAGS;
(SEQ ID NO: 14)
(L-NorLeu)GLHDPSHGTLPAGS;
(SEQ ID NO: 15)
IGLHDPSHGTLPAG-NH2;
(SEQ ID NO: 28)
Ac-IGLHDPSHGTLPAGS-NH2;
(SEQ ID NO: 29)
Ac-IGLHDPSHGTLPAG-NH2;
(SEQ ID NO: 30)
IGLHD PSHGT LPAGS-NH2;
(SEQ ID NO: 41)
IGLHDPSHGTLPAGSC;
(SEQ ID NO: 42)
Ac-IGLHDPSHGTLPAGSC;
(SEQ ID NO: 43)
IGLHDPSHGTLPAGSC-NH2;
(SEQ ID NO: 44)
Ac-IGLHDPSHGTLPAGSC-NH2;
(SEQ ID NO: 45)
IGLHDPSHGTLPAGC;
(SEQ ID NO: 46)
Ac-IGLHDPSHGTLPAGC;
(SEQ ID NO: 47)
IGLHDPSHGTLPAGC-NH2;
(SEQ ID NO: 48)
and
Ac-IGLHDPSHGTLPAGC-NH2.
(SEQ ID NO: 49)
3 . (canceled)
4 . A peptide or analog thereof comprising the sequence:
IGLHDPTQGTEPAGE (SEQ ID NO:50).
5 . The peptide or analog of claim 4 , wherein the peptide or analog comprises a peptide or analog selected from:
IGLHDPTQGTEPAGE;
(SEQ ID NO: 50)
IGLHDPTQGTEP(Aib)GE;
(SEQ ID NO: 51)
Ac-IGLHDPTQGTEPAGE;
(SEQ ID NO: 52)
(D-Ile)GLHDPTQGTEPAGE;
(SEQ ID NO: 53)
Ac-IGLHDPTQGTEPAG-NH2;
(SEQ ID NO: 60)
Ac-IGLHD PTQGT EPAGE-NH2;
(SEQ ID NO: 62)
IGLHDPTQGTEPAGE-NH2;
(SEQ ID NO: 68)
IGLHDPTQGTEPAGC;
(SEQ ID NO: 69)
Ac-IGLHDPTQGTEPAGC;
(SEQ ID NO: 70)
IGLHDPTQGTEPAGC-NH2;
(SEQ ID NO: 71)
and
Ac-IGLHD PTQGT EPAGC-NH2.
(SEQ ID NO: 72)
6 . (canceled)
7 . A peptide or analog thereof comprising a peptide or analog selected from the group consisting of:
Ac-IGLHDPSHGTLPNGS;
(SEQ ID NO: 16)
(D-Ile)GLHDPSHGTLPNGS;
(SEQ ID NO: 17)
Ac-IGLHD PSHGT LPNGS-NH2;
(SEQ ID NO: 31)
IGLHDPSHGTLPNGS-NH2;
(SEQ ID NO: 32)
IGLHDPSHGTLPNGSC;
(SEQ ID NO: 33)
Ac-IGLHDPSHGTLPNGSC;
(SEQ ID NO: 34)
IGLHDPSHGTLPNGSC-NH2;
(SEQ ID NO: 35)
Ac-IGLHDPSHGTLPNGSC-NH2;
(SEQ ID NO: 36)
IGLHDPSHGTLPNGC;
(SEQ ID NO: 37)
Ac-IGLHDPSHGTLPNGC;
(SEQ ID NO: 38)
IGLHDPSHGTLPNGC-NH2;
(SEQ ID NO: 39)
Ac-IGLHDPSHGTLPNGC-NH2;
(SEQ ID NO: 40)
IGLHDPSHGTLPNG;
(SEQ ID NO: 74)
Ac-IGLHDPSHGTLPNG;
(75)
IGLHDPSHGTLPNG-NH2;
(76)
and
Ac-IGLHDPSHGTLPNG-NH2.
(77)
8 - 13 . (canceled)
14 . The peptide or analog of claim 1 , wherein the peptide or analog thereof comprises a modification.
15 . The peptide or analog of claim 14 , wherein the modification is selected from an acetylated N-terminus, an amidated C-terminus, a D amino acid, a modified amino acid, a fatty acid modification, or a combination thereof.
16 . The peptide or analog of claim 1 , wherein the peptide or analog thereof has a length of 20 amino acids or less.
17 . A composition comprising the peptide or analog of claim 1 .
18 - 19 . (canceled)
20 . A method for ameliorating a sign or symptom associated with impaired pancreatic function comprising administering the peptide or analog of claim 1 .
21 . The method of claim 20 , wherein the impaired pancreatic function is type 1 diabetes, type 2 diabetes, latent autoimmune diabetes in adults (LADA), impaired fasting glucose, impaired glucose tolerance, insulin deficiency, fasting hyperinsulinemia, insulin resistance, or impaired fasting insulin level, or a combination thereof.
22 . (canceled)
23 . A method for stimulating pancreatic islet cell growth, comprising contacting a pancreatic islet cell in vitro with the peptide or analog of claim 1 , whereby proliferation of the pancreatic islet cell is stimulated.
24 . A method of producing a population of pancreatic islet cells, comprising contacting one or more pancreatic islet cells in vitro with the peptide or analog of claim 1 , whereby proliferation of the one or more pancreatic islet cells are stimulated and a population of pancreatic islet cells is produced.
25 - 27 . (canceled)
28 . A method for increasing the number of pancreatic islet cells in a subject comprising administering the peptide or analog of claim 1 .
29 . A method for ameliorating a sign or symptom associated with a metabolic disease in a subject comprising administering the peptide of claim 1 .
30 . The method of claim 29 , wherein the metabolic disease is diabetes, pre-diabetes or metabolic syndrome.
31 . A method of reducing in a diabetic subject impaired glucose tolerance, blood glucose, fasting blood glucose, postprandial blood glucose, insulin deficiency, fasting hyperinsulinemia, insulin resistance, impaired fasting insulin levels, glycosylated hemoglobin (HbA1c), arginine-stimulated C-peptide (AUC), or a combination thereof, by administering a peptide or analog of claim 1 to the subject.
32 . A method for promoting neuroprotection or nerve regeneration, comprising contacting a nerve cell with the peptide or analog of claim 1 .
33 . A method for promoting liver regeneration, comprising contacting a liver cell with the peptide or analog of claim 1 .
34 - 35 . (canceled)
36 . A method for inhibiting inflammation, comprising administering the peptide or analog of claim 1 .
37 - 39 . (canceled)Join the waitlist — get patent alerts
Track US2016039877A1 — get alerts on status changes and closely related new filings.
We store only your email — no account needed. See our privacy policy.